329 related articles for article (PubMed ID: 18284419)
1. Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from Cryptococcus neoformans induce macrophage apoptosis mediated by Fas ligand.
Villena SN; Pinheiro RO; Pinheiro CS; Nunes MP; Takiya CM; DosReis GA; Previato JO; Mendonça-Previato L; Freire-de-Lima CG
Cell Microbiol; 2008 Jun; 10(6):1274-85. PubMed ID: 18284419
[TBL] [Abstract][Full Text] [Related]
2. Cryptococcus neoformans glucuronoxylomannan induces macrophage apoptosis mediated by nitric oxide in a caspase-independent pathway.
Chiapello LS; Baronetti JL; Garro AP; Spesso MF; Masih DT
Int Immunol; 2008 Dec; 20(12):1527-41. PubMed ID: 18927317
[TBL] [Abstract][Full Text] [Related]
3. Cryptococcus neoformans capsular polysaccharide component galactoxylomannan induces apoptosis of human T-cells through activation of caspase-8.
Pericolini E; Cenci E; Monari C; De Jesus M; Bistoni F; Casadevall A; Vecchiarelli A
Cell Microbiol; 2006 Feb; 8(2):267-75. PubMed ID: 16441437
[TBL] [Abstract][Full Text] [Related]
4. Capsular localization of the Cryptococcus neoformans polysaccharide component galactoxylomannan.
De Jesus M; Nicola AM; Rodrigues ML; Janbon G; Casadevall A
Eukaryot Cell; 2009 Jan; 8(1):96-103. PubMed ID: 18952901
[TBL] [Abstract][Full Text] [Related]
5. Cryptococcus neoformans galactoxylomannan is a potent negative immunomodulator, inspiring new approaches in anti-inflammatory immunotherapy.
Vecchiarelli A; Pericolini E; Gabrielli E; Chow SK; Bistoni F; Cenci E; Casadevall A
Immunotherapy; 2011 Aug; 3(8):997-1005. PubMed ID: 21843086
[TBL] [Abstract][Full Text] [Related]
6. Systematic capsule gene disruption reveals the central role of galactose metabolism on Cryptococcus neoformans virulence.
Moyrand F; Fontaine T; Janbon G
Mol Microbiol; 2007 May; 64(3):771-81. PubMed ID: 17462022
[TBL] [Abstract][Full Text] [Related]
7. In vivo clearance of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans: a critical role for tissue macrophages.
Grinsell M; Weinhold LC; Cutler JE; Han Y; Kozel TR
J Infect Dis; 2001 Aug; 184(4):479-87. PubMed ID: 11471106
[TBL] [Abstract][Full Text] [Related]
8. Induction of interleukin-6 mRNA in rat alveolar macrophages by in vitro exposure to both Cryptococcus neoformans and anti-C. neoformans antiserum.
Li RK; Mitchell TG
J Med Vet Mycol; 1997; 35(5):327-34. PubMed ID: 9402525
[TBL] [Abstract][Full Text] [Related]
9. Cryptococcus neoformans inhibits nitric oxide production by murine peritoneal macrophages stimulated with interferon-gamma and lipopolysaccharide.
Kawakami K; Zhang T; Qureshi MH; Saito A
Cell Immunol; 1997 Aug; 180(1):47-54. PubMed ID: 9316638
[TBL] [Abstract][Full Text] [Related]
10. Cryptococcus neoformans capsular glucuronoxylomannan induces expression of fas ligand in macrophages.
Monari C; Pericolini E; Bistoni G; Casadevall A; Kozel TR; Vecchiarelli A
J Immunol; 2005 Mar; 174(6):3461-8. PubMed ID: 15749881
[TBL] [Abstract][Full Text] [Related]
11. Production of extracellular polysaccharides by CAP mutants of Cryptococcus neoformans.
Grijpstra J; Gerwig GJ; Wösten H; Kamerling JP; de Cock H
Eukaryot Cell; 2009 Aug; 8(8):1165-73. PubMed ID: 19542308
[TBL] [Abstract][Full Text] [Related]
12. Involvement of the capsular GalXM-induced IL-17 cytokine in the control of Cryptococcus neoformans infection.
LaRocque-de-Freitas IF; Rocha JDB; Nunes MP; Oliveira PAV; Nascimento DO; Freire-de-Lima L; Takiya CM; Morrot A; Decote-Ricardo D; Previato JO; DosReis GA; Mendonça-Previato L; Freire-de-Lima CG
Sci Rep; 2018 Nov; 8(1):16378. PubMed ID: 30401972
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan.
Maitta RW; Datta K; Pirofski LA
Vaccine; 2004 Sep; 22(29-30):4062-8. PubMed ID: 15364457
[TBL] [Abstract][Full Text] [Related]
14. Receptor-mediated clearance of Cryptococcus neoformans capsular polysaccharide in vivo.
Yauch LE; Mansour MK; Levitz SM
Infect Immun; 2005 Dec; 73(12):8429-32. PubMed ID: 16299344
[TBL] [Abstract][Full Text] [Related]
15. The physical properties of the capsular polysaccharides from Cryptococcus neoformans suggest features for capsule construction.
McFadden DC; De Jesus M; Casadevall A
J Biol Chem; 2006 Jan; 281(4):1868-75. PubMed ID: 16278213
[TBL] [Abstract][Full Text] [Related]
16. Glucuronoxylomannan, galactoxylomannan, and mannoprotein occupy spatially separate and discrete regions in the capsule of Cryptococcus neoformans.
Jesus MD; Nicola AM; Chow SK; Lee IR; Nong S; Specht CA; Levitz SM; Casadevall A
Virulence; 2010; 1(6):500-8. PubMed ID: 21178496
[TBL] [Abstract][Full Text] [Related]
17. Enzyme immunoassay detection of IgM to galactoxylomannan of Cryptococcus neoformans.
Reiss E; Cherniak R; Eby R; Kaufman L
Diagn Immunol; 1984; 2(2):109-15. PubMed ID: 6388977
[TBL] [Abstract][Full Text] [Related]
18. Anti-glucuronoxylomannan IgG1 specific antibodies production in Cryptococcus neoformans resistant mice.
Parra C; González JM; Castañeda E; Fiorentino S
Biomedica; 2005 Mar; 25(1):110-9. PubMed ID: 15962907
[TBL] [Abstract][Full Text] [Related]
19. Effects of the capsular polysaccharides of Cryptococcus neoformans on phagocyte migration and inflammatory mediators.
Ellerbroek PM; Walenkamp AM; Hoepelman AI; Coenjaerts FE
Curr Med Chem; 2004 Jan; 11(2):253-66. PubMed ID: 14754421
[TBL] [Abstract][Full Text] [Related]
20. Differences in outcome of the interaction between Cryptococcus neoformans glucuronoxylomannan and human monocytes and neutrophils.
Monari C; Retini C; Casadevall A; Netski D; Bistoni F; Kozel TR; Vecchiarelli A
Eur J Immunol; 2003 Apr; 33(4):1041-51. PubMed ID: 12672070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
